Equine spermatozoa induce a uterine inflammatory response characterized by a rapid, transient influx of polymorphonuclear neutrophils (PMNs). Seminal plasma proteins have been shown to modulate the interaction between spermatozoa and PMNs, but a specific protein responsible for this function has not been identified. The objective of this study was to isolate and identify a protein in equine seminal plasma that suppresses binding between spermatozoa and PMNs. Seminal plasma was pooled from five stallions, and proteins were precipitated in 60% (w/v) ammonium sulfate and dialyzed (3500 MW cutoff). Proteins were submitted to a Sephacryl S200 column, and fractions were pooled based on the fraction pattern. Each pool was analyzed for protein concentration and tested for its suppressive effect on PMN/sperm binding. Protein pools with biological activity were submitted to ion-exchange chromatography (diethylaminoethyl [DEAE] Sephadex column) with equilibration buffers containing 0.1-0.5M NaCl. Eluants were pooled, analyzed for protein concentration, and tested for suppressive effects on PMN/sperm binding. Protein distribution and purity were determined by oneand two-dimensional SDS-PAGE, and the purified protein was submitted for sequence analysis and identification. This protein was identified as equine CRISP3 and was confirmed by Western blotting. Suppression of PMN/sperm binding by CRISP3 and seminal plasma was confirmed by flow cytometry (22.08% 6 3.05% vs. 2.06% 6 2.02% vs. 63.09% 6 8.67 for equine seminal plasma, CRISP3, and media, respectively; P , 0.0001). It was concluded that CRISP3 in seminal plasma suppresses PMNs/sperm binding, suggesting that CRISP3 regulates sperm elimination from the female reproductive tract.
INTRODUCTION
During natural mating or artificial insemination of horses, semen is deposited directly into the uterus. Transport of spermatozoa from the uterus to the oviduct is completed within 4 h after breeding [1] , and only a small portion of the ejaculated or inseminated spermatozoa reach the oviduct [2] . The remainder of the ejaculate is eliminated through the cervix, aided by increased myometrial contractions that are associated with breeding [3] [4] . However, not all excess spermatozoa are removed through this mechanism, and other uterine clearance mechanisms are necessary. A specific immune response with memory would be detrimental to fertility during a subsequent breeding, so elimination of spermatozoa needs to be achieved by a combination of innate immune reactions and mechanical clearance through a second wave of uterine contractions. This mechanism involves a cascade of inflammatory reactions, including activation of inflammatory mediators and an influx of inflammatory cells, such as polymorphonuclear neutrophils (PMNs) into the uterine lumen [5] [6] [7] [8] . PMNs in in vitro and in vivo studies have shown that spermatozoa activate complement in uterine secretions [7, 9] , resulting in an influx of PMNs into the uterine lumen within 0.5 h after breeding [5] [6] 10] . Activated PMNs bind to spermatozoa in a process that appears to be mediated by extracellular neutrophil traps but also involves ligand receptor binding [11] [12] [13] . Following binding to PMNs, spermatozoa are eliminated by phagocytosis, and inflammatory products are eliminated from the uterus by a second wave of contractions, mediated by PGF 2 a [3] . The inflammation appears to be a normal process by which excess sperm are eliminated from the mare reproductive tract [3, 14] . However, the inflammation could potentially be harmful for spermatozoa during its early stage when sperm are still transported through the uterine lumen. It would, therefore, be necessary that a population of viable spermatozoa be protected from binding and phagocytosis by PMNs in order to ensure that sufficient numbers of spermatozoa reach the oviduct for fertilization. This is particularly important when mares are bred repeatedly (i.e., into an existing inflammation).
It has previously been shown that seminal plasma protects spermatozoa from being bound, phagocytosed, and destroyed in an inflammatory environment [15] [16] [17] . In vitro experiments have demonstrated that the effect of seminal plasma on PMN binding and phagocytosis is confined to the protein fraction in seminal plasma [15, 18] . It was shown that this effect was confined to a low-molecular-weight protein within seminal plasma, but a specific protein was not identified in that study [15] . Equine seminal plasma is rich in protein, and the majority of the proteins that have been identified range from 12 kDa to 30 kDa. However, very few of these proteins have been associated with a biological function [19] . The objective of this study was to characterize and identify specific proteins in seminal plasma that are responsible for the suppression of binding between spermatozoa and PMNs.
MATERIALS AND METHODS

Preparation of Seminal Plasma
Five ejaculates were collected from each of five large breed stallions. The stallions were maintained on pasture, and the care and experimentation were conducted in accordance with University of Florida institutional animal care and use regulations. Semen was collected by the use of a Missouri model artificial vagina. Spermatozoa were separated from seminal plasma by centrifugation at 600 3 g for 15 min, and the sperm pellet was resuspended in EquiPro semen extender (Minitube of America, Verona, WI) at a concentration of 50 3 10 6 spermatozoa per ml for use in other experiments. The seminal plasma portion was further submitted to centrifugation at 2000 3 g for 15 min, at 48C, and the spermatozoa were pooled from all five stallions.
Following centrifugation, 2 ml of a protease inhibitor cocktail containing AEBSF [4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride]; bestatin hydrochloride, E-64 [N-9 trans-epoxtsuccinyl)-L-leucine 4-guanidinobutylamine], EDTA, and leupeptin hemisulfate salt (Sigma-Aldrich, St. Louis, MO) was added to each 50 ml aliquot of the pooled seminal plasma samples to inhibit any endogenous protease activity. Aliquots were kept at À808C until use.
Seminal plasma samples were buffered with 25 mM sodium phosphate, pH 7.2, and protein fractions were precipitated with additions of solid ammonium sulfate at 08C in the concentrations of 10%, 35%, 60%, and 80% w/v at 08C. The ammonium sulfate was added slowly to each sample over the course of 30 min under constant stirring in a cold room. Following addition of each ammonium sulfate concentration in a stepwise manner, samples were allowed to equilibrate for an additional 45 min in the cold room under constant stirring. Samples were then centrifuged, 2000 3 g, 30 min, 48C, and the supernatant was removed and resubmitted to ammonium sulfate precipitation with the next higher concentration. The pellet at each state was solubilized and resuspended in phosphate-buffered saline PBS at a total volume equivalent to the original starting volume of seminal plasma fluid. Results showed that 60% (w/v) of saturated ammonium sulfate produced seminal plasma proteins with optimal biological activity, which is in agreement with previous observations [20] . The 60% seminal plasma precipitate was then solubilized and resuspended in a volume of PBS (pH 7.2) equal to the amount of seminal plasma used for precipitation to ensure that the protein concentration was similar to that of the original seminal plasma. Aliquots of the precipitated proteins, the resuspended proteins, and the supernatants were then dialyzed against four changes of PBS for 2 days at 48C in a dialysis cassette (3500 MW cutoff; Slide-A-Lyser, Pierce, Rockford, IL). Following dialysis, the protein concentration for each sample was determined as described previously (Bio-Rad Laboratories, Hercules, CA) [21] . Bovine catalase (Sigma-Aldrich) in concentrations ranging from 0.2 to 2 mg/ml was used as a standard. A protein control of equine serum was fractionated with ammonium sulfate and tested in a manner similar to that used for seminal plasma proteins. Precipitated and resuspended protein fractions were concentrated using Amicon Ultra Centrifugation spin columns (Millipore Co., Billerica, MA), at 30 000 and 10 000 MW cutoff points (3500 rpm, 30 min, 48C). Each sample was centrifuged, and the retained sample (in the top of the spin column) was kept on ice while the flow-through was recentrifuged to maximize the recovery of concentrated proteins. Protein samples were then divided into aliquots of 5 ml volumes each and frozen at À808C until use.
Preparation of Spermatozoa
Three ejaculate samples from each of three stallions were used for all PMN/ sperm binding assays. Semen was collected by the use of a Missouri model artificial vagina. Immediately following collection, semen was extended in a commercial semen extender (EquiPro without antibiotics, Minitube of America) at a ratio of 3 parts extender to 1 part semen. The semen was assessed for quality (volume, concentration, and progressive motility), and only semen showing .50% progressive sperm motility was used for this study.
Preparation of PMNs
A total of 20 ml of venous blood from healthy mares (regardless of the stage of the estrous cycle) was collected from the jugular vein into Vacutainer tubes (BD Biosciences, Rutherford, NJ) containing sodium heparin as anticoagulant. Previous studies have shown that the stage of the estrous cycle has no effect on sperm binding and phagocytosis by blood-derived PMNs (Troedsson, unpublished data) . Blood was centrifuged at 1000 3 g for 10 min, and plasma was removed. The buffy coat was mixed with an isotonic saline solution (0.9 g/ml), layered on lymphocyte separation medium (Organo Teknika, Durham, NC), and centrifuged at 1000 3 g for 20 min at 258C. The PMN-rich buffy coat was collected from the pellet underneath the lymphocyte preparation medium. Distilled water (6 ml) was added to the suspension in order to lyse the red blood cells, and 3 ml of a 2.7% (v/v) NaCl solution was added after 45 sec before centrifugation (1000 3 g, 5 min, 258C). The PMN pellet was resuspended in Hanks buffered salt solution (HBSS) to a final concentration of 14 3 10 6 cells/ml, as described previously [18] .
PMN/Sperm Binding
Microscopic evaluation. A previously described microscopic binding assay was used to evaluate binding between spermatozoa and PMNs [18] . Spermatozoa were separated from seminal plasma by centrifugation (600 3 g, 15 min), and the sperm pellet was resuspended in EquiPro semen extender at a concentration of 50 3 10 6 spermatozoa per ml. Sperm preparations were divided into three aliquots of 5 ml each. Three 1-ml aliquots of spermatozoa from each of the three aliquots were mixed 1:1 with medium (HBSS), whole fresh seminal plasma, or precipitated/purified proteins, at a concentration of 250 lg/ml for a final protein concentration of 125 lg/ml. These combined samples were incubated (30 min, 378C), mixed with 0.5 ml of purified PMNs (14 3 10 6 PMNs/ml), and incubated again (30 min, 378C). A negative control for nonspecific sperm agglutination was prepared in the absence of PMNs, and a positive control for binding was prepared in the absence of seminal plasma, precipitated proteins, or purified proteins. Smears were prepared on microscope slides and stained with a DiffQuick stain (Agauda, PR). Binding was determined at 4003 magnification and expressed as the percentage of PMNs that bound to at least one spermatozoon. A total of 200 spermatozoa per slide were counted. All assays were performed within 2 h of semen collection.
Flow cytometry. Flow cytometry was used to confirm the effect of purified seminal plasma protein on binding between spermatozoa and PMNs. Flow cytometry was performed at the Interdisciplinary Center for Biotech Research (ICBR) core facility at the University of Florida. Cells were analyzed on a FACSort flow cytometer (BD Biosciences). A method was adapted from an equine PMN phagocytosis protocol using bacterial cells [22] and modified for PMN/sperm binding. Spermatozoa appeared in the PMN gate 1.7% of the time at random, when there were no PMNs present (Fig. 1) . Therefore, the gate was set for the size and density of PMNs, and fluorescence was indicated by attachment of spermatozoa to a PMN. PMNs were collected from a healthy mare and prepared as described above to a final concentration of 1.0 3 10 6 cells in 0.8 ml of 13 PBS with 10% v/v fetal calf serum (FCS) (pH 7.0). The PMNs were labeled with dihydrorhodamine (DHR) (500 lM stock solution) dissolved in 5 mM dimethyl sulfoxide for a final concentration of 50 lM DHR and incubated in a water bath (378C, 1 h). Spermatozoa were prepared at a concentration of 25 3 10 6 cells in 0.8 ml of 13 PBS with 10% (v/v) FCS (pH 7.0). The sperm preparation was labeled with Qtracker 655 (Molecular Probes, Eugene, OR) at a concentration of 10 nM (2 ll/million cells) and incubated (378C, 1 h) in a water bath. Binding assays were prepared as described above. Aliquot samples were prepared with and without seminal plasma protein (125 lg/ml in 0.8 ml of total volume). A control sample of PMNs only (without spermatozoa or seminal plasma proteins) served as a negative control, and a sample including seminal plasma was used as a positive control. A total of 5 ml of 13 PBS, pH 7.2, was added to each sample before loading into the FACSort flow cytometer for recording of the kinetics. The gate that had been selected on the forward scatter vs. side scatter histogram, based on inclusion of equine PMNs but exclusion of single sperm, was labeled R1. Qdot 655-labeled sperm were detected in the FL3 channel (650 nm bandpass filter) with 488 nm laser excitation. The percentage of cells positive for the Qdot 655 signal in the R1 gate represented PMNs that have bound to a labeled sperm. Fluorescent signal of Qdot 655 was measured as the output.
Fractionation by Gel Filtration
The ammonium sulfate fraction of seminal plasma (60%, w/v) containing biological activity (inhibition of binding between PMNs and spermatozoa) was submitted to a Sephacryl S200 column (3 3 100 cm) previously equilibrated and eluted with 50 mM PBS, pH 7.2, containing 5 mM EDTA and 0.02% (w/v) sodium azide. The column was calibrated using a mixture of standards, dextran blue, bovine serum albumin (67 kDa), ovalbumin (45 kDa), and soybean trypsin inhibitor (20 kDa). Fractions (6 ml) were monitored at 280 nm. The collected fractions were pooled based on the A 280 elution profile. Pooled fractions were dialyzed against 4 L of PBS buffer (pH 7.2), in which the buffer was changed four times over a 48-h period. The protein concentration was determined as described above [21] , and the samples were concentrated by Amicon Ultra Spin columns 10 000 MW cutoff (Millipore Co.). Each pool was assayed for biological activity (inhibition of PMN/spermatozoa binding) using evaluation by microscopy. Protein distribution and purity of the isolated fractions were determined by SDS-PAGE. 
Ion-Exchange Chromatography
The gel filtration pool that was determined to be biologically active was applied to a 2.5 3 20 cm diethylaminoethyl (DEAE) Sephadex column (BioRad) previously equilibrated with 50 mM PBS containing 0.01 M NaCl, 5 mM EDTA, and 0.02% (w/v) sodium azide, pH 7.2. After being loaded and washed, the bound material was eluted in a stepwise manner (10 ml fractions) with equilibration buffer containing 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, and 0.5 M NaCl. Each of the eluants was pooled, dialyzed (PBS, pH 7.2, 4 l, four changes, 48 h), analyzed for protein concentration as previously described, and concentrated by Amicon Ultra spin columns, 10 000 MW cutoff (Millipore Co.). Biological activity (inhibition of PMN/spermatozoa binding) of each fraction was determined using microscopy evaluation of sperm/PMN binding. Protein distribution and purity in each pool were determined by one-dimensional and two-dimensional SDS-PAGE (1D-and 2D-SDS-PAGE).
1D-and 2D-SDS-PAGE
Protein distribution and characterization were performed by 1D-and 2D-SDS-PAGE. All 1D-SDS-PAGE, using 10% (w/v) bisacrylamide gels, were focused on the Miniprotean II system (Bio-Rad). Aliquots of concentrated proteins (250 lg/ml) from ion-exchange chromatography were dialyzed (PBS, pH 7.2, 4 l, four changes, 48 h), lyophilized, and resuspended in solubilization buffer. Pooled protein fractions were lyophilized and separated by 2D-SDS-PAGE electrophoresis, using 3-10 nonlinear 8 cm Immobiline dry strips (Amersham Biochemicals, Carlsbad, CA) for isoelectric focusing (20 h, 158C, 20 Vh), and by 10% SDS-PAGE gels in the second dimension [23] [24] [25] . All gels were stained with Coomassie blue stain (0.05%, w/v).
Sequence Analysis and Identification
All sequence analysis and database searching were performed at the ICBR Proteomics Core laboratory at the University of Florida. Sequence analysis was performed by in-gel tryptic digestion and tandem mass spectrometry (MS/MS) protein analysis. The 2D excised gel spots were reduced, alkylated, and digested with trypsin (Promega) in gel. Capillary reverse-phase high-pressure liquid chromatography (HPLC) separation of protein digests was performed using a PepMap C18 column (15 cm 3 75 lm inner diameter) and an Ultimate capillary HPLC system (LC Packings, San Francisco, CA). A linear gradient of 5% to 40% (v/v) acetonitrile for 25 min at 200 nl/min was used for separation. MS/MS analysis was performed online using a hybrid quadrupole time-of-flight instrument (QSTAR XL hybrid LC/MS/MS) equipped with a nanoelectrospray source (Applied Biosystems) and operated with Analyst QS version 1.1 data acquisition software.
Information-dependent acquisition, in which each cycle consisted of a full scan from m/z 400 to 1500 (1 sec) followed by MS/MS (3 sec) of the two ions that exhibited the highest signal intensity, was used. In the full scan acquisition mode, ions were focused through the first quadrupole by focusing and declustering potentials of 275 V and 55 V, respectively, and guided to the timeof-flight region via two quadrupole filters operated in radio frequency-only mode. Ions were orthogonally extracted, accelerated through the flight tube (plate, grid, and offset voltages were 340, 380, and À15 V, respectively), and refocused to a four-anode micro channel plate detector via an ion mirror held at 990 V. The same parameters were utilized with the MS/MS mode of operation; however, the second quadrupole was used to filter a specific ion of interest, while the third quadrupole operated as a collision cell. Nitrogen was used as the collision gas, and collision energy values were optimized automatically using the rolling collision energy function based on m/z and the charge state of the peptide ion.
Database Searching
MS/MS spectra were extracted by Analyst QS version 1.1 software (Applied Biosystems). All MS/MS samples were analyzed using Mascot version 2.2.0 software (Matrix Science, London, U.K.). Mascot was set up to search the NCBI_20100312 (10 570 301 sequences), assuming the digestion enzyme trypsin. Mascot searched with a fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 0.50 Da. Iodoacetamide derivative of cysteine was specified in Mascot as a fixed modification. S- Carbamoylmethylcysteine   FIG. 1 . Representative scattergrams and analysis of fluorescence output of an individual assay of sperm binding to PMNs is shown, using a modified PMN Escherichia coli phagocytosis protocol for flow cytometry. A total of 125 lg/ml of protein (seminal plasma and purified CRISP3) was added to the sperm/PMN suspension. Control gate (A) for Qdot-labeled sperm occurring randomly in PMN gate; control media treatment (B); seminal plasma treatment (C); CRISP3 purified from seminal plasma (D).
CRISP3 MODULATES SPERM/PMN BINDING cyclization (N terminus) of the N terminus, deamidation of asparagine and glutamine, and oxidation of methionine were specified in Mascot as variable modifications.
Immunoblotting of Purified CRISP3
A monoclonal equine anti-CRISP3 immunoglobulin G (IgG) clone, 4D8, was produced by the ICBR Hybridoma Core Laboratory at the University of Florida. Full-length, purified CRISP3 from equine seminal plasma was used to immunize mice from which antibodies were harvested. The clone was selected using the ''unknown'' purified CRISP3. Truncated peptide sequences of CRISP3 were produced and also tested for antigenicity in mice, but they did not induce an antigenic response. For Western blotting, purified CRISP3 from the ion-exchange column was diluted and boiled for 5 min in reducing SDS-PAGE sample buffer and subjected to 12% (w/v) bisacrylamide 1D-SDS-PAGE. 
Statistical Analysis
All analyses were carried out using the STATISTIX version 8.0 program. Samples were assayed in triplicate, and the means of the assays were compared among treatment groups. All data were tested for normal distribution. Comparisons between treatments were analyzed using a one-way analysis of variance (ANOVA) and a Bonferroni comparison test if normally distributed and by a Kruskal-Wallis ANOVA if not normally distributed. All data were expressed as means 6 SEM. Significance was set at a P value of ,0.05.
RESULTS
Biological Activity of Ammonium Sulfate Precipitated Proteins
Following ammonium sulfate precipitation of seminal plasma, dialysis, and concentration, the 60% fraction was found to significantly suppress PMN/sperm binding compared to all other fractions and the extender alone (P , 0.0001) (Fig.  2) . The suppression by the 60% fraction was similar to that of PMN/sperm binding in the presence of seminal plasma.
Biological Activity of Gel Filtration Fractionated Protein Pools
The addition of the 60% ammonium sulfate fraction to the Sephacryl S200HR column and its subsequent elution yielded two major A 280 peaks. Fractions of these peaks were pooled, generating a total of six pools (Fig. 3) . Aliquots from each of the six pools were then tested for their effect on binding between PMNs and spermatozoa (Fig. 4) . Pools 4 and 5 suppressed PMN/sperm binding compared to all other pools (P , 0.0001). The suppression was similar to PMN/sperm binding in the presence of seminal plasma.
Biological Activity of Ion-Exchange Fractionated Protein Pools
The gel filtration fractionated pooled samples (Fig. 3 , pools 4 and 5) with significant suppression of PMN/sperm binding were loaded onto an anion-exchange column. Proteins were separated and eluted batch-wise by various salt concentrations from 0.1 M to 0.5 M NaCl. Each elution fraction was tested for protein concentration and for biological activity in PMN/sperm binding assays. The 0.1 M-0.2M fractions showed significant suppression of PMN/sperm binding (P , 0.05), similar to that of seminal plasma controls (Fig. 5 ). There was a dosedependent suppression of PMN/sperm when the ion-exchange pooled fractions (0.1 þ 0.15 þ 0.2 M NaCl fraction) were combined and tested. The combined purified protein fractions suppressed PMN binding at 125 lg/ml (P , 0.05) (Fig. 6 ), whereas lower concentrations had no detectable effect on binding between spermatozoa and PMNs. Electrophoresis by 1D-SDS-PAGE showed distinct protein bands from tested pools. The proteins were larger than 21 kDa and smaller than 35 kDa, and appeared as a doublet band (Fig. 7) . The larger molecular weight band was more prominent in the 0.1 M pool, equal to the smaller molecular mass band in the 0.15 M pool and smaller in the 0.2 M pool, suggesting that these bands were further separable for analysis.
Identification and Sequence Analysis of Protein Spots
The three pools, 0.1 M, 0.15 M, and 0.2 M, were combined and subjected to 2D-SDS-PAGE, which revealed two families of closely related proteins (Fig. 8) . The purified protein was submitted for sequence analysis and identification (see Supplemental Fig. S1 and Supplemental Table S1 , available online at www.biolreprod.org). MS/MS spectra identified nine unique peptides with 11 unique spectra (26 total spectra). There was a 39% coverage rate (95/245 total positive amino acids) with equine CRISP3 (GenBank accession no. NP_001075343) (Fig. 9) .
Western Blotting
The glycosylated and nonglycosylated forms of purified CRISP3 were detected by Western blotting in the whole seminal plasma, the 60% ammonium sulfate precipitated protein fractions, and the ion-exchange chromatography 0.1 to 0.2 M pools, using an equine monoclonal CRISP3 antibody (Fig. 10) . Purified equine CRISP3 was detected using a human CRISP3 polyclonal antibody (see Supplemental Fig. S2A) ; however, recombinant human CRISP3 did not cross-react with the equine monoclonal CRISP3 antibody (Supplemental Fig.  S2B ).
Flow Cytometry
Following identification of CRISP3 as the protein of interest, the effect of this protein on binding between   FIG. 4 . Binding of spermatozoa to PMNs in the presence of seminal plasma and protein fractions (pools 1 to 6) following gel filtration chromatography of seminal plasma proteins. A total protein concentration of 125 lg/ml was used from each fraction. Binding is expressed as the percentage of PMNs that bind at least one spermatozoon.
ab Different letters indicate significant differences; P , 0.0001.
FIG. 5.
Binding of spermatozoa to PMNs in the presence of seminal plasma and eluted protein fractions following ion-exchange chromatography with buffers containing 0.1 M to 0.5 M NaCl, PB Wash (PB wash ¼ phosphate buffer wash) and media. Binding is expressed as the percentage of PMNs that bind at least one spermatozoon.
abc Different letters indicate significant differences; P , 0.05. CRISP3 MODULATES SPERM/PMN BINDING spermatozoa and PMNs was confirmed by the use of flow cytometry. There was a significant suppression of PMN/sperm binding by seminal plasma and the purified protein (CRISP3) compared to that of medium controls (22.08% 6 3.05% vs. 2.06% 6 2.02% vs. 63.09% 6 8.67%, respectively; P , 0.0001) (Fig. 11) .
DISCUSSION
The maintenance of biological activity through the purification process and the overall high yield and purity of CRISP3 demonstrated that proteins in seminal plasma can be successfully isolated by chromatography without loss of biological activity. CRISP3 has previously been shown to be a major component of equine seminal plasma, but little information is available on the biological role of this protein [26] [27] . To our knowledge, this is the first report of a specific function for CRISP3 in the horse. Under the conditions of this study, CRISP3 suppressed PMN/sperm binding in a dose-dependent manner. Equine seminal plasma and the total extracted protein fraction of seminal plasma have previously been shown to suppress PMN-binding and phagocytosis of spermatozoa [15, [17] [18] . Alghamdi and Foster [12] showed that DNase present in seminal plasma could prevent binding between PMNs and spermatozoa through its effect on extracellular neutrophil traps. However, the suppression was only partial, and no specific protein in seminal plasma was identified that is responsible for the greater suppression of binding between PMNs and spermatozoa. Our results suggest that CRISP3 plays a major role in this process. Purified CRISP3 was dialyzed using a 10 kDa molecular mass cutoff tubing and, thus, does not appear to be complexed with b-microseminoprotein, a 10 kDa protein present in high concentrations in seminal plasma [28] . Protecting spermatozoa from PMN-binding and phagocytosis is of importance during sperm transport to the oviduct [3] . It is not clear if suppression of binding between PMNs and spermatozoa is a selective process involving a subset of viable and normal spermatozoa, or if the process is nonselective for all spermatozoa. A selective suppression of viable spermatozoa would allow effective sperm elimination of dead and abnormal sperm from the uterus without interfering with transport of sperm to the oviduct. This would clearly be beneficial for effective sperm transport and elimination from the mare's reproductive tract. Further studies are necessary to clarify this.
Three CRISP proteins, identified as CRISP1, CRISP2, and CRISP3, have been identified in humans, mice, rats, and horses. CRISP1 is also known as D/E protein in rats [29] [30] , acidic epididymal glycoprotein (AEG) in mice [31] , and ARP (AEG-related protein) in humans [32] . In addition, CRISP4 has been identified in the mouse and rat [33, 34] . The CRISP family is believed to play a role in binding of sperm to the oocyte [26, 30, [35] [36] [37] , and CRISP1 has been shown to be involved in the inhibition of premature sperm capacitation [30, 38] . Equine epididymis secretes CRISP1 and CRISP3 into the epididymal lumen. Human CRISP1 protein has been detected in all regions of the epididymis, vas deferens, and seminal plasma [39] . Hardy et al. [40] found that CRISP2 is the only CRISP normally expressed in the mammalian testis. Equine CRISP3, which is produced in seminal vesicles, is similar in 162 structure to other mammalian CRISP proteins, with 16 strictly conserved cysteine residues in the carboxy terminal region. Human and equine CRISP3 are reported to share a 66% amino acid sequence identity [26] [27] 41] . CRISP3 has been identified in the male reproductive tract in the human and horse. In addition, CRISP3 shows a wide expression pattern in mouse, including exocrine tissues and the female reproductive tract [42] . Both humans and equines have isoforms of CRISP1 within the reproductive tract, and it has been suggested that CRISP1 and CRISP3 have overlapping or similar functions [26-27, 41, 43-45] .
Equine CRISP3 was first characterized and sequenced by Magdaleno et al. [43] , and it was suggested that the protein could play a role in host defense or membrane fusion events. Schambony et al. [26] suggested CRISP3 is a major seminal plasma protein that can be found in concentrations as high as 1 mg/ml in stallions. CRISP3 suppressed binding between PMNs and spermatozoa at a concentration of .125 lg/ml under the in vitro conditions of this study. Uterine secretion amounts to less than 5 ml in mares prior to breeding (Troedsson, unpublished observation) . When mares are bred by natural cover, adequate concentrations of CRISP3 should therefore be present in the uterus. The expression and the abundance of CRISP3 in the ampulla and seminal vesicles of the horse are unique, and the protein has been found in stallion spermatozoa [26, 27, 43] . A positive relationship between CRISP3 in seminal plasma and stallion fertility was recently reported [46] . That finding supports a previous study by Hamann et al. [36] in which Hanoverian warmblood breeding stallions that were homozygous for CRISP3 had a 7% increase in fertility rates. The mechanism of CRISP3 in enhancing fertility has not been investigated. Our data suggest that one effect of CRISP3 in fertility may occur through its role in sperm transport and elimination. This needs to be further investigated.
Flow cytometric analysis was more accurate in recognizing PMN/sperm binding compared to a previously described microscopic assay [18] . This is not surprising. In order for a PMN/sperm combination to appear in the set gates in the flow cytometer, the cells must be tightly bound to one another. In addition, the microscopy assay is subjective and dependent on the personal interpretation of binding. However, the microscopically observed binding may still be valid as a quick method of preliminary screening of samples prior to analysis by flow cytometry.
In summary, for the first time, we have described a biological function for equine CRISP3 in seminal plasma. CRISP3 has previously been associated with fertility, yet no suggested explanation on how the protein functions in regards to promoting fertility in the horse has been offered. Further research needs to be done to determine the binding mechanism between PMNs and spermatozoa, as well as the mechanism by which CRISP3 protects spermatozoa from binding to PMNs and consequently being eliminated from the uterus. FIG. 11 . Binding of spermatozoa to PMNs in the presence of a medium control, equine seminal plasma, and CRISP3 purified from seminal plasma, as described in the text. A total concentration of 125 lg/ml of purified CRISP3 was used. Spermatozoa were obtained from five ejaculate samples from each of five stallions, and each sample was assayed in triplicate.
abc Different letters indicate significant differences; P , 0.0001.
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